BACKGROUND: Lower respiratory viral infections predispose to bronchiolitis obliterans syndrome (BOS). In addition, there is emerging evidence to support the role of autoimmunity in the pathogenesis of BOS. Because CD4(+)CD25(+)Foxp3(+) regulatory T-cells (Treg) control autoimmunity, we tested the hypothesis that respiratory virus-induced Treg dysfunction leads to BOS. METHODS: Treg frequency was monitored using flow cytometry. Apoptosis, cytokines, and antibodies were analyzed using annexin V assay, LUMINEX, and enzyme-linked immunosorbent assay, respectively. Murine studies were performed using the orthotopic tracheal transplant model. RESULTS: (A) Human studies: Treg troughs (decrease >50% of baseline) were found in 13 (43.3%) of 30 lung transplant recipients. Treg isolated during troughs revealed increased apoptosis (37.8%). Patients with Treg troughs had increased prevalence of antibodies to self-antigens collagen type I (23.1% vs 5.8% pretrough), collagen V (7.7% vs 0%), and k-alpha tubulin (30.7% vs 11.7%, p < 0.01) at 6 months post-trough. Increased number of Treg troughs correlated with more rapid onset of BOS. (B) Murine studies: Infection of tracheal transplant recipients with murine parainfleunza sendai virus led to increased Treg apoptosis (50.5%) in the draining lymph nodes. Vaccination against sendai virus prior to transplant abrogated apoptosis of Treg. In vitro, sendai virus-infected, but not naive, tracheal epithelial cells demonstrated upregulation of FasL (>3.5-fold) and induction of co-cultured Treg apoptosis (5.6-fold increase). CONCLUSIONS: Respiratory viral infections cause Treg apoptosis which leads to the development of de novo autoimmunity that may play a role in the pathogenesis of BOS.
BACKGROUND: Lower respiratory viral infections predispose to bronchiolitis obliterans syndrome (BOS). In addition, there is emerging evidence to support the role of autoimmunity in the pathogenesis of BOS. Because CD4(+)CD25(+)Foxp3(+) regulatory T-cells (Treg) control autoimmunity, we tested the hypothesis that respiratory virus-induced Treg dysfunction leads to BOS. METHODS:Treg frequency was monitored using flow cytometry. Apoptosis, cytokines, and antibodies were analyzed using annexin V assay, LUMINEX, and enzyme-linked immunosorbent assay, respectively. Murine studies were performed using the orthotopic tracheal transplant model. RESULTS: (A) Human studies: Treg troughs (decrease >50% of baseline) were found in 13 (43.3%) of 30 lung transplant recipients. Treg isolated during troughs revealed increased apoptosis (37.8%). Patients with Treg troughs had increased prevalence of antibodies to self-antigens collagen type I (23.1% vs 5.8% pretrough), collagen V (7.7% vs 0%), and k-alpha tubulin (30.7% vs 11.7%, p < 0.01) at 6 months post-trough. Increased number of Treg troughs correlated with more rapid onset of BOS. (B) Murine studies: Infection of tracheal transplant recipients with murineparainfleunza sendai virus led to increased Treg apoptosis (50.5%) in the draining lymph nodes. Vaccination against sendai virus prior to transplant abrogated apoptosis of Treg. In vitro, sendai virus-infected, but not naive, tracheal epithelial cells demonstrated upregulation of FasL (>3.5-fold) and induction of co-cultured Treg apoptosis (5.6-fold increase). CONCLUSIONS:Respiratory viral infections cause Treg apoptosis which leads to the development of de novo autoimmunity that may play a role in the pathogenesis of BOS.
Authors: Ramsey R Hachem; Anthony P Khalifah; Murali M Chakinala; Roger D Yusen; Aviva A Aloush; Thalachallour Mohanakumar; G Alexander Patterson; Elbert P Trulock; Michael J Walter Journal: Transplantation Date: 2005-11-27 Impact factor: 4.939
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: R E Girgis; I Tu; G J Berry; H Reichenspurner; V G Valentine; J V Conte; A Ting; I Johnstone; J Miller; R C Robbins; B A Reitz; J Theodore Journal: J Heart Lung Transplant Date: 1996-12 Impact factor: 10.247
Authors: Anthony P Khalifah; Ramsey R Hachem; Murali M Chakinala; Kenneth B Schechtman; G Alexander Patterson; Daniel P Schuster; Thalachallour Mohanakumar; Elbert P Trulock; Michael J Walter Journal: Am J Respir Crit Care Med Date: 2004-05-06 Impact factor: 21.405
Authors: Teruaki Mizobuchi; Kazuhiro Yasufuku; Yan Zheng; M Azizul Haque; Kathleen M Heidler; Kena Woods; Gerald N Smith; Oscar W Cummings; Takehiko Fujisawa; Janice S Blum; David S Wilkes Journal: J Immunol Date: 2003-08-01 Impact factor: 5.422
Authors: Félix G Fernández; Andrés Jaramillo; Chang Chen; Daniel Z Liu; Thomas Tung; G Alexander Patterson; T Mohanakumar Journal: Am J Transplant Date: 2004-03 Impact factor: 8.086
Authors: Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn Journal: Semin Immunopathol Date: 2011-01-27 Impact factor: 9.623
Authors: Michael E Seifert; Muthukumar Gunasekaran; Timothy A Horwedel; Reem Daloul; Gregory A Storch; Thalachallour Mohanakumar; Daniel C Brennan Journal: J Am Soc Nephrol Date: 2016-11-07 Impact factor: 10.121
Authors: Ankit Bharat; Martín Angulo; Haiying Sun; Mahzad Akbarpour; Andrés Alberro; Yuan Cheng; Masahiko Shigemura; Sergejs Berdnikovs; Lynn C Welch; Jacob A Kanter; G R Scott Budinger; Emilia Lecuona; Jacob I Sznajder Journal: Am J Respir Cell Mol Biol Date: 2020-08 Impact factor: 6.914
Authors: V Tiriveedhi; M Takenaka; S Ramachandran; A E Gelman; V Subramanian; G A Patterson; T Mohanakumar Journal: Am J Transplant Date: 2012-07-23 Impact factor: 8.086
Authors: Ramiro Fernandez; Stephen Chiu; Kirtee Raparia; Puneet Garcha; Carol Farver; Marie Budev; Anat R Tambur; Malcolm M DeCamp; Scott Budinger; Harris Perlman; T Mohanakumar; Ankit Bharat Journal: Ann Thorac Surg Date: 2016-10 Impact factor: 4.330